MIRCERA

Clinical safety rating: caution

Comprehensive clinical and safety monograph for MIRCERA (MIRCERA).

How it works

MIRCERA (methoxy polyethylene glycol-epoetin beta) is a continuous erythropoietin receptor activator that stimulates erythropoiesis by binding to and activating the erythropoietin receptor, leading to increased red blood cell production.

What the body does with it

Metabolism	MIRCERA is primarily eliminated via the reticuloendothelial system and not metabolized by cytochrome P450 enzymes. Minor degradation occurs via proteolysis.
Excretion	Renal (minimal, as MIRCERA is a large glycoprotein that is not significantly filtered by the glomerulus). The majority is eliminated via binding to EPO receptors on target cells followed by internalization and degradation, with less than 10% excreted unchanged in urine. Biliary/fecal elimination is negligible.
Half-life	Terminal half-life approximately 130-140 hours (about 5-6 days) in patients with chronic kidney disease. This long half-life supports once-monthly dosing. In healthy volunteers, half-life is about 134 hours.
Protein binding	Approximately 50-60% bound to serum proteins, primarily albumin, though binding is reversible and not restrictive.
Volume of Distribution	Approximately 3.3 L in a 70 kg patient (about 0.047 L/kg), indicating limited distribution primarily to plasma volume. This reflects the large molecular weight of the methoxy polyethylene glycol-epoetin beta conjugate, which restricts extravascular distribution.
Bioavailability	Subcutaneous: Approximately 62% relative to intravenous administration. Peak serum concentration occurs 72-120 hours post-dose. Absolute bioavailability not determined due to the drug's endogenous comparators.
Onset of Action	Subcutaneous: Increase in hemoglobin typically observed within 2-4 weeks after initiation. Intravenous: Similar onset, with reticulocyte count increases detectable within 1-2 weeks.
Duration of Action	Subcutaneous: Effect on hemoglobin levels persists for the entire monthly dosing interval (4 weeks). Continuous erythropoiesis stimulation is maintained with regular administration, with hemoglobin rise continuing for up to 4 weeks after a single dose in some studies.

Classification & Brands

Action Class

Erythropoiesis-stimulating agent (ESA)

Dosing & administration

Initial dose 0.6 mcg/kg intravenously or subcutaneously every 2 weeks; for patients not on dialysis, initial dose 1.2 mcg/kg subcutaneously every 2 weeks; target hemoglobin 10-12 g/dL.

Dosage form	SOLUTION
Renal impairment	No dose adjustment required for GFR <30 mL/min; use with caution in patients with chronic kidney disease not on dialysis; monitor hemoglobin closely.
Liver impairment	No specific Child-Pugh based dosing; use with caution in severe hepatic impairment; no clinical data available.
Pediatric use	Not approved for pediatric patients; safety and efficacy not established.
Geriatric use	No specific dose adjustment for elderly; initial dose based on body weight; monitor hemoglobin and iron status.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for MIRCERA (MIRCERA).

Breastfeeding	Unknown if excreted in human milk. Caution advised. M/P ratio not determined.
Teratogenic Risk	Pregnancy Category B. Animal studies show no evidence of fetal harm. No adequate human studies in first trimester. Use only if clearly needed. Potential increased risk of thrombotic events in pregnant women.
Fetal Monitoring	Monitor hemoglobin levels weekly during initiation and periodically thereafter. Monitor blood pressure regularly. Assess for adverse thrombotic events. Fetal ultrasound if significant maternal anemia develops.

Warnings & precautions

■ FDA Black Box Warning

WARNING: ESAs increase the risk of death, myocardial infarction, stroke, venous thromboembolism, vascular access thrombosis, and tumor progression or recurrence. To reduce these risks, use the lowest dose sufficient to avoid red blood cell transfusion. For patients with chronic kidney disease, use only when hemoglobin is <10 g/dL and individualize dosing to maintain hemoglobin between 10-12 g/dL. Not indicated for use in patients with cancer receiving myelosuppressive chemotherapy when the anticipated outcome is cure.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Uncontrolled hypertension","History of serious allergic reactions to MIRCERA or any of its components","Pure red cell aplasia after prior ESA therapy"]

Clinical Precautions

Precautions

["Increased mortality and cardiovascular events","Increased risk of thrombotic events and vascular access thrombosis","Increased mortality in cancer patients not receiving myelosuppressive chemotherapy","Hypertension","Seizures","Pure red cell aplasia due to anti-erythropoietin antibodies","Serious allergic reactions including anaphylaxis","Tumor progression in cancer patients"]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

MIRCERA

Clinical safety rating: caution

Comprehensive clinical and safety monograph for MIRCERA (MIRCERA).

How it works

What the body does with it

Metabolism	MIRCERA is primarily eliminated via the reticuloendothelial system and not metabolized by cytochrome P450 enzymes. Minor degradation occurs via proteolysis.
Excretion	Renal (minimal, as MIRCERA is a large glycoprotein that is not significantly filtered by the glomerulus). The majority is eliminated via binding to EPO receptors on target cells followed by internalization and degradation, with less than 10% excreted unchanged in urine. Biliary/fecal elimination is negligible.
Half-life	Terminal half-life approximately 130-140 hours (about 5-6 days) in patients with chronic kidney disease. This long half-life supports once-monthly dosing. In healthy volunteers, half-life is about 134 hours.
Protein binding	Approximately 50-60% bound to serum proteins, primarily albumin, though binding is reversible and not restrictive.
Volume of Distribution	Approximately 3.3 L in a 70 kg patient (about 0.047 L/kg), indicating limited distribution primarily to plasma volume. This reflects the large molecular weight of the methoxy polyethylene glycol-epoetin beta conjugate, which restricts extravascular distribution.
Bioavailability	Subcutaneous: Approximately 62% relative to intravenous administration. Peak serum concentration occurs 72-120 hours post-dose. Absolute bioavailability not determined due to the drug's endogenous comparators.
Onset of Action	Subcutaneous: Increase in hemoglobin typically observed within 2-4 weeks after initiation. Intravenous: Similar onset, with reticulocyte count increases detectable within 1-2 weeks.
Duration of Action	Subcutaneous: Effect on hemoglobin levels persists for the entire monthly dosing interval (4 weeks). Continuous erythropoiesis stimulation is maintained with regular administration, with hemoglobin rise continuing for up to 4 weeks after a single dose in some studies.

Classification & Brands

Action Class

Erythropoiesis-stimulating agent (ESA)

Dosing & administration

Initial dose 0.6 mcg/kg intravenously or subcutaneously every 2 weeks; for patients not on dialysis, initial dose 1.2 mcg/kg subcutaneously every 2 weeks; target hemoglobin 10-12 g/dL.

Dosage form	SOLUTION
Renal impairment	No dose adjustment required for GFR <30 mL/min; use with caution in patients with chronic kidney disease not on dialysis; monitor hemoglobin closely.
Liver impairment	No specific Child-Pugh based dosing; use with caution in severe hepatic impairment; no clinical data available.
Pediatric use	Not approved for pediatric patients; safety and efficacy not established.
Geriatric use	No specific dose adjustment for elderly; initial dose based on body weight; monitor hemoglobin and iron status.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for MIRCERA (MIRCERA).

Breastfeeding	Unknown if excreted in human milk. Caution advised. M/P ratio not determined.
Teratogenic Risk	Pregnancy Category B. Animal studies show no evidence of fetal harm. No adequate human studies in first trimester. Use only if clearly needed. Potential increased risk of thrombotic events in pregnant women.
Fetal Monitoring	Monitor hemoglobin levels weekly during initiation and periodically thereafter. Monitor blood pressure regularly. Assess for adverse thrombotic events. Fetal ultrasound if significant maternal anemia develops.

Warnings & precautions

■ FDA Black Box Warning

Side Effect Profile

Serious Effects

Absolute Contraindications

["Uncontrolled hypertension","History of serious allergic reactions to MIRCERA or any of its components","Pure red cell aplasia after prior ESA therapy"]